Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2002
02/28/2002WO2002015909A1 Substituted piperidines as melanocortin receptor agonists
02/28/2002WO2002015908A1 Injections
02/28/2002WO2002015907A1 Use of flupirtine to treat tinnitus
02/28/2002WO2002015906A1 2-3-disubstituted quinuclidines as modulators of monoamine transporters and therapeutic and diagnostic methods based thereon
02/28/2002WO2002015905A1 The use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
02/28/2002WO2002015904A1 Methods of drug delivery to hepatocytes and treatment of flaviviridae infections
02/28/2002WO2002015903A2 Novel pharmaceutical composition for administering n-0923
02/28/2002WO2002015902A1 Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
02/28/2002WO2002015901A1 Myricetin as an inhibitor of serotonin n-acetyltransferase
02/28/2002WO2002015900A1 Ibuprofen solutions for capsule-filling and capsule prepartions
02/28/2002WO2002015899A1 Combination therapy for the treatment of migraine
02/28/2002WO2002015898A1 Topically applied hoof treatment composition concentrate
02/28/2002WO2002015897A2 Use of sublethal concentrations of anti-invasin compounds to therapeutically or prophylactically treat fungal infections
02/28/2002WO2002015895A2 Alpha-difluoromethylornithine (dfmo) use in the human prostate
02/28/2002WO2002015894A2 Use of vitamin d derivatives as bone resorption inhibitors
02/28/2002WO2002015893A2 Treatment of wounds
02/28/2002WO2002015892A2 Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors
02/28/2002WO2002015891A2 Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors
02/28/2002WO2002015890A1 Transdermal therapeutic system
02/28/2002WO2002015889A1 Transdermal therapeutic system for treating restless-legs-syndrome
02/28/2002WO2002015886A2 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor
02/28/2002WO2002015885A2 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
02/28/2002WO2002015884A2 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
02/28/2002WO2002015881A2 Use of a porous carrier
02/28/2002WO2002015878A1 Aqueous suspension preparations
02/28/2002WO2002015871A1 Use of tyramine in cosmetic compositions to lighten the skin
02/28/2002WO2002015868A2 Cosmetic formulation containing at least one di-sugar alcohol phosphate of c3 to c6 sugar alcohols
02/28/2002WO2002015867A1 Use of beta-mannosylglycerate and derivatives in cosmetic and dermatological formulations
02/28/2002WO2002015866A2 Use of cyclic 2,4-diphosphoglycerates (cdgp) and/or derivatives thereof in cosmetic and dermatological formulations
02/28/2002WO2002015851A2 Storage stable tretinoin and 4-hydroxy anisole containing topical composition
02/28/2002WO2002015845A2 Anti-hypercholesterolemic drug combination
02/28/2002WO2002015842A2 Process for preparation of anhydrous azithromycin
02/28/2002WO2002015841A2 Medicine for treating female sexual dysfunction by acting on the central nervous system
02/28/2002WO2002015832A1 Non-hormonal vaginal contraceptive
02/28/2002WO2002015809A2 Dental composition for hypersensitive teeth
02/28/2002WO2002015722A2 Treatment of helicobacter with isothiocyanates
02/28/2002WO2002015721A2 Foodstuff and animal feedstuff supplement compositions
02/28/2002WO2002015699A1 Probes for targeting of cell density-indicating compounds
02/28/2002WO2002015664A2 Methods of preventing or treating west nile virus and other infections
02/28/2002WO2002009667A9 Dispersions for formulating slightly or poorly soluble active ingredients
02/28/2002WO2002000221B1 Enhanced brain function by gaba-ergic stimulation
02/28/2002WO2001093853B1 Management of snoring by oral administration of dimethyl sulfone
02/28/2002WO2001087887A3 Neuroprotective and anti-proliferative compounds
02/28/2002WO2001087236A3 Topical administration of pharmacological compositions for non-systemic treatment of pruritus
02/28/2002WO2001087234A3 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers
02/28/2002WO2001085779A3 Protein complexes and assays for screening anti-cancer agents
02/28/2002WO2001085762A3 Cancer diagnosis and assays for screening anti-cancer agents
02/28/2002WO2001085699A3 Prodrugs of hiv replication inhibiting pyrimidines
02/28/2002WO2001082860A3 Use of ursodeoxycholic acid for potentiation of the phototoxic effect of photodynamic therapy
02/28/2002WO2001081343A3 Compounds for treating fibromyalgia and chronic fatigue syndrome
02/28/2002WO2001080809A3 Medicament for the treatment of diseases caused by parasitic protozoa
02/28/2002WO2001080713A3 Methods for non-permanent occlusion of a uterine artery
02/28/2002WO2001079167A3 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
02/28/2002WO2001078531A3 Conjugated linoleic acid powder
02/28/2002WO2001077377A8 Diagnosis of diseases associated with dna replication by assessing dna methylation
02/28/2002WO2001077080A3 Pyrazole compounds having anti proliferative activity
02/28/2002WO2001076530A3 Il-8 receptor antagonists
02/28/2002WO2001072281A3 Microspheres for active embolization
02/28/2002WO2001070720A3 Carbocyclic side chain containing, n-substituted metalloprotease inhibitors
02/28/2002WO2001070255A3 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
02/28/2002WO2001070224A3 Rilmenidine dressing and method for preparing same
02/28/2002WO2001068654A3 Tubulin binding ligands and corresponding prodrug constructs
02/28/2002WO2001066545A3 1,8-NAPHTHALIMIDE IMIDAZO[4,5,1-de]ACRIDONES WITH ANTI-TUMOR ACTIVITY
02/28/2002WO2001066084A3 Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
02/28/2002WO2001064663A3 Biologically active analogs of discodermolide
02/28/2002WO2001064639A3 Pde iv inhibiting amides, compositions and pharmaceutical use
02/28/2002WO2001064254A3 Engineered spray-dried lipid-based microparticles for cellular targeting
02/28/2002WO2001060347A3 Method for treating ocular pain
02/28/2002WO2001058936A3 Constructs for delivery of therapeutic agents to neuronal cells
02/28/2002WO2001053321A3 Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers
02/28/2002WO2001046200A8 Novel piperidine and piperazine derivatives
02/28/2002WO2001045714A3 Formulations of adenosine a1 agonists
02/28/2002WO2001045685A3 Formulations of adenosine a1 agonists
02/28/2002WO2001045661A3 Cosmetic and/or pharmaceutical preparations
02/28/2002WO2001042216A3 Caspase inhibitors and uses thereof
02/28/2002WO2001041769A3 Combination of cyamemazine and an atypical neuroleptic
02/28/2002WO2001036656B1 A complex between hyaluronic acid and a biomolecule and its use
02/28/2002WO2001028975A3 Method for production of 3-nitryloxy-2,2-bis(nitryloxymethyl)-propanal
02/28/2002WO2001026638A3 The use of baclofen in the treatment of alcoholism
02/28/2002WO2001025469A3 Method for preparing steroids modified by yeast fermentation
02/28/2002WO2001024804A3 Method for preparing a composition by mother-of-pearl extraction, and use thereof in cosmetics and dermatology
02/28/2002WO2001024783A3 Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
02/28/2002WO2001017614A3 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents
02/28/2002WO2001015755A3 Methods and compositions for delivery of pharmaceutical agents
02/28/2002WO2001015672A3 Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
02/28/2002WO2001007026A3 Improved method of treating type ii diabetes and obesity
02/28/2002WO2001005422A3 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease
02/28/2002WO2001001970A3 New uses potassium channel openers, such as the treatment of epilepsy
02/28/2002WO2000077037A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same
02/28/2002WO2000073307A8 Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors
02/28/2002WO2000067746A8 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
02/28/2002WO2000067733A3 Medicament for treating human infertility
02/28/2002WO2000040569A9 2-amino-benzoxazinone derivatives for the treatment of obesity
02/28/2002US20020026236 Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia
02/28/2002US20020026158 Synchronising of animal oestrus and intra vaginal devices useful therein
02/28/2002US20020026062 Method for the preparation of citalopram
02/28/2002US20020026060 RAR selective retinoid agonists
02/28/2002US20020026059 Use as microbicides in crop protection
02/28/2002US20020026056 Substituted imidazoles having cytokine inhibitory activity
02/28/2002US20020026055 Aminopyridine-containing thiourea inhibitors of herpes viruses